Abstract:Background: A malignant tumor's immune environment, including infiltrating immune cell status, can be critical to patient outcomes. Recent studies have shown that immune cell infiltration (ICI) in pancreatic cancer (PC) is highly correlated with the response to immunotherapy and patient prognosis. Therefore, we aimed to create an ICI score that accurately predicts patient outcomes and immunotherapeutic efficacy. Methods: The ICI statuses of patients with PC were estimated from the publicly available The Cancer Genome Atlas (TCGA) pancreatic ductal adenocarcinoma and GSE57495 gene expression datasets using two computational algorithms (CIBERSORT and ESTIMATE). ICI and transcriptome subsets were defined using a clustering algorithm, and survival analysis was also performed. Principal component analysis was used to calculate the novel ICI score, and gene set enrichment analysis was performed to identify the pathways underlying the defined clusters. The tumor mutational burden (TMB) was further explored in TCGA cohort, and survival analysis was used to assess the capability of the ICI and TMB scores to predict overall survival. Additionally, common driver gene mutations and their differential expression in the different ICI score group were investigated. Results: The ICI landscapes of 240 patients were generated using the devised algorithm, revealing three ICI and three gene clusters whose use improved the prediction of overall survival (p = 0.019 and p < 0.001, respectively). Crucial immune checkpoint genes were differentially expressed among these subtypes; the RIG-I-LIKE and NOD-LIKE receptor signaling pathways were enriched in samples with low ICI scores (p < 0.05). We also found that the TMB scores could predict survival outcomes, whereas the ICI scores also could predict prognoses independent of TMB. Notably, ICI scores could effectively predict responses to immunotherapy. KRAS, TP53, CDKN2A, SMAD4 and TTN remained the most commonly mutated genes in PC; moreover, KRAS and TP53 mutation rates were significantly different between the two ICI score groups. Conclusions: We developed a novel ICI score that could independently predict the response to immunotherapy and survival of patients with PC. Evaluation of the ICI landscape in a larger cohort could clarify the interactions between these infiltrating cells, the tumor microenvironment and response to immunotherapy. Lay abstract Pancreatic cancer (PC) is a lethal malignancy with a higher mortality rate. Currently, immunotherapy is increasingly interesting to clinical researchers and considered a novel and efficient treatment. However, in clinical practice, immunotherapy has not demonstrated consistent therapeutic responses across all patients. Thus, to identify the immunotherapy-sensitive subgroup of advanced PC patients is important based on immune cell infiltration. In this study, we downloaded and processed transcriptomic data from TCGA-PAAD and GEO databases and used CIBERSORT and ESTIMATE algorithms to reveal the immune cell infiltration landscape of pancreatic cancer. According to consensus clustering results, we identified three ICI and gene clusters for guiding the identification of immune-subtype in future clinical treatments. Finally, we calculated an ICI score for each subject to describe their tumor immune landscape and performed the risk grouping for all patients and multiomics analysis. In sum, the ICI score and clusters could be used in the future to assist clinicians in identifying patients with the greatest chance of responding to immunotherapy.

Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Tumor Microenvironment Assessment-Based Signatures for Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature As an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response

Cellular Dynamics Upon Immune Checkpoint Inhibition

Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy

Endogenous retrotransposable elements as a novel predictive biomarker of response to immunotherapy.

Identification of the Immune Cell Infiltration Landscape in Pancreatic Cancer to Assist Immunotherapy.

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts

Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy

Abstract 6425: Harnessing big data from pan-cancer concerning more than 1300 patients with immune checkpoint inhibitors identifies novel predictive biomarkers

Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy

Abstract 2534: Single-cell dissection of heterogeneity and dynamics of tumor ecosystem upon immune-checkpoint blockade in hepatocellular carcinoma

A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy

Comprehensive Analysis to Identify IL7R As a Immunotherapy Biomarker from Pan-Cancer Analysis to in Vitro Validation.

Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment

Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma

Exploring the Immune Landscape of ccRCC: Prognostic Signatures and Therapeutic Implications